Rezdiffra is a treatment for non-alcoholic steatohepatitis (NASH) developed by Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals Stock in Focus After New Patents

Q: Why are traders interested in Madrigal stock?

Traders are interested due to speculation about a potential acquisition by Eli Lilly, which could result in a premium.

Madrigal Pharmaceuticals announced three new U.S. patents for its lead drug Rezdiffra, drawing retail trader attention and fueling M&A speculation.

July 14, 2026

1 min read

Source: Stocktwits

Madrigal Pharmaceuticals (MDGL) announced on Friday that it has received three new U.S. patents for its lead drug Rezdiffra. The news sparked significant interest among retail traders on Stocktwits, with the stock trending amid speculation about a potential acquisition by Eli Lilly (LLY).

Patent Details

The new patents cover various aspects of Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH). The company did not provide further details on the scope of each patent.

Context

This development comes amid a wave of M&A activity in the pharmaceutical industry, particularly in liver disease treatments. Rezdiffra is considered one of the most promising therapies in this space, making Madrigal an attractive acquisition target.

What It Means for Investors

While the patents strengthen Madrigal's competitive position, the acquisition speculation remains unconfirmed. Investors should monitor regulatory developments and future clinical data to better assess the likelihood of a deal.

Frequently Asked Questions

Madrigal received three new U.S. patents for its lead drug Rezdiffra, but details were not disclosed.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.